Company Overview - Novocure Limited (NASDAQ: NVCR) develops wearable devices that generate Tumor Treating Fields (TTFields) for the treatment of aggressive cancers [1] - The company has approved devices such as Optune and Optune Gio specifically for treating glioblastoma (GBM) [1] Product Details - Optune Lua is another device developed by Novocure, aimed at assisting in cancer treatment [1]

The Ozempic maker's stock is dropping fast -- here's why.Shares of Novo Nordisk (NVO -21.38%) are plunging on Tuesday, down 21% as of 2:10 p.m. ET. The drop comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) both lost 0.3%.The Danish pharmaceutical giant announced it was cutting its full-year guidance ahead of its upcoming earnings on Aug. 6. The news overshadowed the company's appointment of a new CEO.Novo names new CEO and cuts guidanceOn Tuesday, Novo Nordisk named Mike Doustdar as the company ...

For the quarter ended June 2025, NovoCure (NVCR) reported revenue of $158.81 million, up 5.6% over the same period last year. EPS came in at -$0.36, compared to -$0.31 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $153.83 million, representing a surprise of +3.24%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being -$0.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Core Viewpoint - Novocure's fiscal Q2 2025 results showed a 6% increase in revenue year-over-year, exceeding Wall Street expectations, while the company continues to develop noninvasive treatments for solid-tumor cancers [3][5]. Financial Performance - Revenue for Q2 2025 was $158.8 million, compared to $150.4 million in Q2 2024, marking a 6% increase [2]. - Earnings per share for Q2 2025 were -$0.36, slightly worse than -$0.31 in Q2 2024, but still beating expectations [2]. - Gross margin decreased to 74% from 77%, a decline of 300 basis points attributed to new product rollout costs [2][4]. - Total active patients increased from 3,963 in Q2 2024 to 4,331 in Q2 2025, a growth of 9% [2]. Product Development and Market Strategy - Revenue from the Optune Lua lung cancer treatment was $2.4 million, following its U.S. approval last fall [3]. - The company plans to seek FDA premarket approval for treatments targeting pancreatic and brain cancers by the end of the year, with trial data expected in the first half of 2026 [6]. Market Reaction - The market response to the results was muted, with Novocure's stock up about 2% in premarket trading, indicating that the results were largely in line with expectations [5]. Long-term Outlook - Despite the current progress, Novocure's stock has seen a significant decline of over 92% from its 2021 high due to previous disappointing trial results, highlighting the inherent risks in biotech investments [7].

Financial Data and Key Metrics Changes - The company reported net revenues of $159 million, an increase of 6% from the second quarter of the previous year, driven by a 7% year-over-year active patient growth in the GBM franchise [28][34] - Gross margin for the second quarter was 74%, down from 77% in the same quarter last year, primarily due to the rollout of the HIV rate and the continued launch of non-small cell lung cancer [30][34] - The net loss for the quarter was $40 million, with a loss per share of $0.36, and adjusted EBITDA was negative $10 million [34][35] Business Line Data and Key Metrics Changes - The company received 121 prescriptions for non-small cell lung cancer in the second quarter, with 106 in the U.S. and 15 in Germany, leading to $2.4 million in net revenues from OptuneLua [15][16] - The active patient count for Optune GEO reached 4,194, a 7% increase compared to the previous year, with all key markets experiencing double-digit growth [23][26] - The METIS trial demonstrated a 28% risk reduction in time to intracranial progression for patients treated with TT Fields therapy compared to supportive care alone [12] Market Data and Key Metrics Changes - The company is actively engaged in discussions with Japanese regulators for the launch of OptuneLua for non-small cell lung cancer, anticipating approval soon [21] - The company has seen promising feedback from peer-to-peer conversations with physicians, indicating a healthy mix of new and repeat prescribers for Tumor Treating Fields therapy [19][20] Company Strategy and Development Direction - The company aims to extend survival for patients with aggressive forms of cancer through the development of Tumor Treating Fields therapy, with ongoing efforts to gain approvals in new indications, particularly pancreatic cancer [5][11] - The company is focused on execution and has reached multiple milestones, including the launch of OptuneLua and the advancement of clinical trials for new indications [15][26] - The company plans to file PMA submissions for pancreatic cancer and brain metastases from non-small cell lung cancer in the near future, with potential approvals and launches expected in 2026 [13][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing launch of OptuneLua and the potential for significant growth in the coming years, particularly in the U.S. and Japan [21][35] - The management highlighted the importance of real-world evidence and peer-to-peer connections in driving adoption of Tumor Treating Fields therapy among physicians [19][20] - The company is committed to balancing investments in launches and future innovations while aiming for profitability, with a target revenue level of around $750 million to achieve adjusted EBITDA profitability [74] Other Important Information - The company is working on minimizing tariff exposure related to imports, with an estimated full-year P&L impact of up to $7 million [31] - The company has a cash and investment balance of $912 million, which is expected to support the retirement of convertible notes and bridge to new revenue streams [34][35] Q&A Session Summary Question: Why was the growth in non-small cell lung cancer prescriptions lower in Q2 compared to Q1? - Management indicated that the launch is progressing as expected, with a consistent ability to educate physicians and build volume [40][42] Question: How different were the METIS numbers disclosed compared to ASCO last year? - The management explained that the METIS trial's endpoint was progression, and the final data set confirmed statistical significance, which was a common practice in trials [46] Question: What is the path to profitability and timeframe? - The management stated that they are on track with expectations and aim for profitability at a revenue level of around $750 million, but did not provide a specific timeframe [74] Question: Are there plans to pursue combinations with other chemotherapy regimens for pancreatic cancer? - The management confirmed that they are actively discussing new combinations and will have data from the PANOVA-four trial in the first half of next year [75][76] Question: How does the NCCN guideline ranking influence commercial coverage? - Management noted that any improvement in ranking is helpful, and they are eager to see updated guidelines published later this fall [57] Question: Does the $94 million in U.S. sales include OptuneLua revenue? - Management confirmed that the $94 million includes all revenue from both Optune GO and Optune Lua [94]

Confidential © 2024 Novocu © 2025 re GmbH Novocure GmbH 1 © 20254 Novocure GmbH GmbH 4 © 2025 Novocure GmbH 2 2025 key objectives, unlocking TTFields potential | DRIVING COMMERCIAL | ADVANCING | DELIVERING | | --- | --- | --- | | ADOPTION | CLINICAL PIPELINE | PRODUCT INNOVATION | | ✔ NSCLC drive global active | ✔ PANOVA-3 present and | V Launch MyNovocure | | patient growth and | publish data | patient app | | pursue reimbursement | • PANOVA-3 submit to FDA, | • New array utilized by | | ✔ NSCLC CE Mark | ...

Novocure Reports Second Quarter 2025 Financial Results Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. ...

Commission File Number 001-37565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Not Applicable NovoCure Limited (Exact Name of Registrant as Specif ...

Financial Performance & Market Position - Novocure reported 2024 net revenue of $605 million[13] - The company has over 4,000 global active patients on therapy[13] - Novocure has established a strong foundation and is building towards profitability[13] Clinical Pipeline & Development - Novocure has commercially launched in Non-Small Cell Lung Cancer (NSCLC)[15] - Positive Phase 3 data was reported in Brain Metastases from NSCLC and Locally Advanced Pancreatic Cancer[15] - Regulatory submissions for Brain Metastases from NSCLC (METIS) and Locally Advanced Pancreatic Cancer (PANOVA-3) are planned for H2 2025[17, 28] - The company is advancing label-expanding clinical trials and investing in its platform for future expansion opportunities[31] Clinical Trial Results - The PANOVA-3 Phase 3 clinical trial showed a statistically significant improvement in pain-free survival, with a median pain-free survival of 15.2 months in the TTFields + GnP group compared to 9.1 months in the GnP group (HR = 0.74)[24, 25] - The one-year pain-free survival rate in the TTFields + GnP group was 54.1%[25] Key Objectives - Novocure aims to drive global active patient growth in NSCLC and pursue reimbursement[30]

Company Overview - NovoCure (NVCR) shares increased by 5.3% to close at $18, supported by higher trading volume compared to normal sessions, following an 11.9% decline over the past four weeks [1][2] Product Development - The rise in stock price is linked to growing investor optimism regarding the development and commercialization of Tumor Treating Fields (TTFields) devices, specifically Optune Gio and Optune Lua, which are approved for treating solid tumor cancers [2] Financial Performance - NovoCure is expected to report a quarterly loss of $0.40 per share, reflecting a year-over-year decrease of 29%. Revenue is anticipated to be $152.48 million, representing a 1.4% increase from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - NovoCure holds a Zacks Rank of 2 (Buy) and is part of the Zacks Medical - Biomedical and Genetics industry. In comparison, Kymera Therapeutics, another company in the same industry, saw a 3.5% decline in its stock price, despite a 51.1% return over the past month [5] - Kymera Therapeutics has experienced a 5.8% increase in its consensus EPS estimate over the past month, now projected at -$0.84, which is a 44.8% decrease from the previous year [6]